Conversations: Mert Guler and Angelo Capone, Purves Redmond

Researchers personally trying MDMA, a new company on the block, financial results for MindMed (MMED / MNMD / MMQ) & Compass Pathways (CMPS) & news on Numinus Wellness (NUMI) & Red Lights Holland (TRIP/TRUFF), this is what we will be covering in today’s episode.

Timestamps:
0:00 – Intro
0:18 – FDA clears researchers to test MDMA on themselves
1:55 – MindMed (MMED / MNMD) announces Q1 Financials
4:30 – Compass Pathways (CMPS) announces Q1 Financials
6:56 – Numinus Wellness (NUMI) supplies psilocybin extract to Optimi Health
8:17 – Red Light Holland (TRIP / TRUFF) has a new app called ‘iMicro’
9:31 – Wesana Health Holdings (WESA) begins trading on the CSE

Link to the FDA clearing researchers to test MDMA on themselves:
https://www.marijuanamoment.net/fda-clears-researchers-to-study-mdma-use-by-therapists-being-trained-in-psychedelic-medicine/

Link to Mindmed’s Q1 2021 Financial report and business highlights:
https://www.newswire.ca/news-releases/mindmed-announces-2021-q1-financial-results-cash-balance-of-160m-usd-194m-cad-to-execute-on-diverse-clinical-pipeline-816112809.html

Link to Compass Pathways (CMPS) Q1 Financial report:https://www.globenewswire.com/news-release/2021/05/13/2228969/0/en/COMPASS-Pathways-plc-announces-financial-results-and-business-highlights-for-the-first-quarter-2021.html

Link to Numinus (NUMI) supplying psilocybin extract to Optimi Health:
https://psilocybinalpha.com/news/numinus-wellness-and-optimi-health-submit-all-natural-psilocybin-extract-to-health-canada-for-pre-clinical-trial-application

Link to Red Light Holland’s (TRIP / TRUFF) new app ‘iMicro’:
https://investingnews.com/news/agriculture-investing/red-light-holland-imicro-digital-care-app-and-telecounseling-goes-live/

Link to Wesana Health Holdings (WESA):
https://psilocybinalpha.com/news/wesana-health-commences-trading-on-the-cse

Image source: https://www.google.com/search?q=mike+tyson&rlz=1C1CHBF_enCA821CA821&sxsrf=ALeKk01FAUv0g0uK0yvLRLlkKOCgPEda6g:1621187634437&source=lnms&tbm=isch&sa=X&ved=2ahUKEwiagcLI4s7wAhWSF1kFHUeECgsQ_AUoAnoECAEQBA&biw=1600&bih=699#imgrc=Hwv5W22HvZQ3QM

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #CMPS

Scientists Create A New DMT: Can it Treat Depression? | Psychedelic Therapy

When it comes to treating mental health conditions with psychedelic therapy, one of the most promising compounds is DMT, the main ingredient in the brew ayahuasca. While DMT may have many potential advantages over other similar compounds such as psilocybin, for example, its short duration of effect, the hallucination can be very intense.

It is an open question whether the mental health benefits we see from psychedelic therapy are due to the experience one undergoes when having a hallucination, or whether it comes strictly from the drug’s effects on the brain. If it is the latter, then hypothetically speaking, we could create a version of DMT that does not cause a hallucination.

Enter Psilera Biosciences.

Psilera is a psychedelic medicines company working to create next-generation psychedelics for use in therapeutic settings. Specifically, they aim to create non-psychedelic versions of classical psychedelics such as psilocybin, LSD and DMT.

PSIL-002 is Psilera’s version of non-hallucinogenic DMT. They recently completed a pre-clinical trial in mice that showed that their version of DMT was safe and non-psychedelic. Now they have to show that their version of DMT can treat depression and addiction, starting with alcoholism.

If Psilera’s DMT can treat these mental health conditions equally as well as regular DMT, but without the intense hallucination, then PSIL-002 would probably be the better compound.

It is exciting to see Psilera’s scientists working on answering the following questions:

Can DMT treat depression?
Can psychedelics help with depression?
Can psychedelics help with Mental Health?

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Video editing: @themyaholy @Psy_holy

#DMT #DEPRESSION #PSYCHEDELICTHERAPY